New drug tested for Tough-to-Treat advanced cancers
NCT ID NCT05311397
Summary
This early-stage study is testing a new drug called A166 in people with advanced HER2-positive solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug shows early signs of helping shrink tumors. The study will enroll about 120 adults who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.